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ABSTRACT
Objective: To examine the validity of a newly developed
prediction model translating osteoarthritis (OA)-speciﬁc
health-related quality of life (HRQL) scores measured using
the Western Ontario and McMaster Osteoarthritis Index
(WOMAC) into generic utility-based HRQL scores measured
using the Health Utilities Index Mark 3 (HUI3).
Methods: Preintervention data from 145 patients with hip
OA and complete WOMAC and HUI3 baseline assessments
from the Alberta Hip Improvement Project study were used
to validate three utility prediction models. These models were
estimated using data from a previous study of knee OA
patients. Predictive performance was assessed using the mean
absolute prediction error (MAE) criterion and several other
criteria.
Results: The validation sample appeared healthier (on the
basis of the HUI3 and WOMAC) than the subjects used to
estimate the prediction models. Nevertheless, the validation
sample outperformed the predictive performance of the
model sample. The results from the validation sample
support the conclusions from the original study in that the
primary model identiﬁed during model development (a model
using WOMAC subscales, their interactions, their square
terms, age, OA duration, their square terms, and gender)
performed better on the MAE criterion than competing
models.
Conclusion: These results support the external validity of the
prediction model for the retrospective estimation of HUI3
utility scores for use in economic evaluation.
Keywords: Health Utilities Index, osteoarthritis, QALY,
regression analysis, Western Ontario and McMaster Osteoar-
thritis (WOMAC) Index.
Introduction
Measurement of health-related quality of life (HRQL)
has become increasingly common in clinical and policy
research, and has been particularly important in
evaluating interventions to manage chronic diseases,
such as osteoarthritis (OA), that affect multiple health
domains, including pain and mobility, over a long
period. Most OA trials measure HRQL using the
Western Ontario and McMaster Osteoarthritis Index
(WOMAC) scale, an OA-speciﬁc HRQL instrument.
The WOMAC allows for the computation of an
overall total measure of HRQL using a weighted sum
of the responses to each of the individual items. It does
not, however, provide a generic, preference-based
summary measure of HRQL.
A preference-based single summary score of HRQL
is a “standardized” measure of health outcome. It
facilitates the comparison of effectiveness of different
interventions targeted at different health conditions,
even if these conditions have different effects on sur-
vival and/or different health domains. Preference-
based measures of HRQL are commonly expressed as
utility scores. The utility score is a measure of prefer-
ence for a state of health relative to “anchor” states;
it is customary to assign a utility value of 1.0 for
“normal health” and 0.0 for “dead.” Intermediate
health states are assigned utility values between 0 and
1, based on the relative desirability of that state [1–3].
The utility score for health states experienced by
patients can be combined with the length of time spent
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in these states to produce a total number of quality-
adjusted life-years (QALYs) over the time frame of the
comparison. QALYs are the most commonly used
metric for cost-utility analysis (CUA) [4]; CUA in turn
is the standard approach for assessing the value for
money spent on health technologies. Indeed, demon-
stration of value for money is commonly required
by insurers considering coverage of new health
technologies.
It would be useful then if WOMAC scores could be
reliably mapped to a preference-based measure of
HRQL for use in situations where preference-based
HRQL data were not collected within the study. Groo-
tendorst et al. [5] have developed and estimated such a
prediction model. Their preferred model mapped
WOMAC scores, along with basic demographic and
OA disease severity data, into Health Utilities Index
(HUI3) utility scores. The HUI3 is a commonly used
measure of the utility or value that the general popu-
lation places on different health states [1,6,7]. The
models developed by Grootendorst et al. [5] were esti-
mated using data from a prospective study of patients
with OA of the knee that evaluated the cost-
effectiveness of hylan G-F 20. Although Grootendorst
et al. [5] report that the HUI3 prediction models per-
formed well in predicting out-of-sample utility scores,
there is no evidence on the predictive performance of
this model in a completely independent group of OA
patients. We therefore generated such evidence and
report our results here.
Methods
Data Source for Prediction Model Development—Hylan
G-F 20 Study
Data for initial prediction model development were
obtained from a previously reported multicenter, ran-
domized, controlled, open-label study of 1-year dura-
tion, performed from 1996 to 1997, where patients
were randomized to either “appropriate care with
hylan G-F 20 (AC + H)” or “appropriate care without
hylan G-F 20 (AC).” Patients in this study had symp-
tomatic knee OA of mild to moderate severity and had
received prior treatment with analgesics. Patients ran-
domized to the AC + H group received hylan G-F 20
administered as a series of three intra-articular injec-
tions at intervals of 1 week, were followed for 1 year,
and were assessed by the clinical investigator at base-
line and 12 months and by telephone interview at
months 1, 2, 4, 6, 8, 10 and 12. Further details per-
taining to study design are provided in Grootendorst
et al. [5] and Raynauld et al. [8].
Prediction models were developed using data on an
intent-to-treat population that included 2186 assess-
ments available for patients in either treatment group
(n = 255). Some patients randomized to AC “crossed
over” because they sought Synvisc® (hylan G-F 20;
Biomatrix Inc., Ridgeﬁeld, NJ) treatment either on
their own or through the investigator during the course
of the trial. Data after crossover were excluded from
the analysis. Moreover, assessments with incomplete
data were excluded, leaving observations on 1833
complete assessments.
Prediction Model Development
Regression models were developed to predict HUI3
utility scores as a function of subjects’ WOMAC score,
demographics, and OA severity. Several predictive
models were assessed. All models incorporated either
the individual item questions from the WOMAC (i.e.,
patient ratings of the extent of impairment to mobility
and the degree of pain and stiffness along a ﬁve-point
Likert scale ranging from “none” to “extreme”) or the
WOMAC subscales based on the responses to the indi-
vidual item questions [9]. The models varied in the
demographic (age, gender) and clinical (OA duration
and Kellgren x-ray grade) variables included.
Each model was assessed by its ability to predict
HUI3 scores using out-of-sample data from the hylan
G-F 20 study, that is, data from the study not used to
develop the model. The primary criterion identiﬁed a
priori for assessing model performance was the mean
absolute error (MAE). For comparison purposes, all
regression models were also evaluated on the root
mean square error (RMSE), intraclass correlation coef-
ﬁcient (ICC), and mean error (ME) criteria (see section
on External Validation of Prediction Models for
descriptions of these criteria). For each model and each
of the criteria, bootstrapping was used to estimate a
mean criterion value (MAE, RMSE, ICC, or ME) and
its 95% conﬁdence interval. Further details pertaining
to prediction model development are provided in
Grootendorst et al. [5].
Prediction Models
Final prediction models included WOMAC subscale
scores along with their pairwise interactions to allow
for nonlinearity. A total of four prediction models were
developed:
Model 1: WOMAC subscales along with their
interactions.
Model 2: WOMAC subscales along with their interac-
tions as well as age, age squared, and gender.
Model 3 (primary model): WOMAC subscales, along
with their interactions, age, OA duration (in the
study knee), and their second-order terms as well as
gender.
Model 4: WOMAC subscales, their interactions, age,
duration of OA (in the study knee), and the squares
of age and OA duration as well as gender and indi-
cators of Kellgren x-ray grade.
Although model 4 outperformed model 3 on the
MAE criterion, we nevertheless selected model 3 as our
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primary model given that the difference in perfor-
mance was slight and it is likely that many potential
users of the prediction models would lack data on
x-ray grade.
External Validation of the Prediction Models
Validation data source—Alberta Hip Improvement
Project (HIP) study. The external validation data set
consisted of hip OA patients from the Alberta HIP
Study. This study compared the efﬁcacy, cost-
effectiveness, and long-term safety of “alternative hip
bearing surfaces” versus “conventional hip arthro-
plasty device surfaces.” Patients needing hip replace-
ments or resurfacing were selected as candidates for
the study when they presented to surgeons in orthope-
dic ofﬁces. The data collected contain information
from patient interviews, orthopedic ofﬁce charts, sur-
gical and hospital charts, and administrative data
sources at baseline, months 3, 6, 9, 12, and 18 after hip
arthroplasty and yearly thereafter. A total of 145
patients with complete data for the WOMAC, HUI3,
age, gender, and OA duration at the baseline assess-
ment were used to validate the model algorithm.
Patients needing hip replacements or resurfacing were
selected when they presented to surgeons in orthopedic
ofﬁces.
The duration of OA and Kellgren x-ray grades
were not speciﬁed as part of the original study
design; as such, the model prediction estimates could
not be examined without making assumptions about
baseline x-ray grade. Consequently, model 4 was not
considered in the validation because x-ray grade was
not a study design element in the Albert HIP Study.
For the purpose of validation, only baseline patient
assessment data were considered. Postbaseline obser-
vations were not used because of the nature of the
intervention, which essentially altered the patient’s
fundamental OA status because the arthritic hip was
replaced.
Methods for Handling Missing Data and
Imputation—External Validation
There were no missing observations for the HUI3. The
scores for patients with missing responses to the
WOMAC subscales were imputed as suggested in the
respective scoring manual [9]. Two patients who had
missing data for the time from onset of OA were
excluded from the analysis. For the WOMAC, 2
patients had imputed values for the pain subscale, 1
patient had an imputed value on the stiffness subscale,
and 70 patients had imputed values on the function
subscale. Of those patients with imputed values on the
function subscale, the majority (66 of 70) were due
solely to missing responses to function item 17, which
addresses “light domestic duties” (males 44% missing;
females 47% missing).
Baseline comparison of the patient populations (devel-
opment vs. external validation). The characteristics of
the patient population from the hylan G-F 20 study
were compared with the patient population of the
Alberta HIP Study data set. Clinical and demographic
variables, the WOMAC total and subscale scores, the
domains of the HUI, and overall score were compared
descriptively at baseline. Continuous variables were
compared using an unpaired t-test, and a chi-square
test was used to compare nominal data.
Validation of Prediction Models
Each eligible patient’s baseline data from the Alberta
HIP Study validation data set were used for validating
the model.
The following four measures of predictive perfor-
mance and the 95% conﬁdence interval were estimated
for each of the models developed by Grootendorst
et al. [5]. Three of the four criteria (ME, MAE, and
RMSE) are derived as a function of the forecast error
(the difference between a subject’s actual and predicted
HUI3 score) of all subjects in the validation sample.
The ME is the average of the forecast errors. The MAE
is the average of the absolute forecast errors. The
RMSE is the positive square root of the average
squared forecast error. The fourth criterion, the ICC, a
measure of agreement, is the ratio of the between-
subject variability to the total residual variability from
a two-way mixed model ANOVA.
Mean error is useful in assessing the ability of
a model to predict group-level (average) HUI3
scores—in this case, the patient-speciﬁc idiosyncratic
components of HUI3 tend to cancel each other out. In
contrast, MAE, ICC, and RMSE are useful for assess-
ing prediction at the individual patient level. We used
bootstrapping to evaluate the performance of the pre-
dictive models. For each of 1000 bootstrapped repli-
cations, 145 patients were sampled with replacement
from the Alberta HIP Study validation data set. For
each replication, the criteria (MAE, RMSE, ICC, and
ME) were calculated for the predicted scores from each
of the three predictive models. The mean criterion
values and 95% conﬁdence intervals for each criterion
applied to each predictive model were calculated as the
2.5th percentile and 97.5th percentile of the distribu-
tion of resulting bootstrapped values.
Software
Statistical analyses were conducted using R software
version 2.1.0 (R Development Core Team, 2005) [10]
and SAS version 8.2 [11].
Results
Baseline Comparability
The mean age of the 145 subjects from the Alberta
HIP Study was 46.9 years, signiﬁcantly younger
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than the 255 subjects from the hylan G-F 20 predic-
tion model sample, which had a mean age of
63.1 years (P < 0.001, Table 1). The gender distribu-
tion between the two studies also differed: Only 32%
of the subjects in the validation data were female
compared with 70% in the prediction model sample
(P < 0.001, Table 1). This was likely due to the strin-
gent exclusion criteria of the validation sample in
which women of childbearing age were not allowed
to participate. The body-mass index of the subjects
in the validation sample was signiﬁcantly lower
(P < 0.001) than the model sample subjects (26.7 vs.
32.5 kg/m2, respectively). The majority of subjects in
both studies were white. The years since the onset of
OA, and SF-36 physical and mental component scales
were not statistically signiﬁcantly different between
the two sample groups. No inferences were made
regarding the differences in x-ray grade between the
two population samples, as grading for the validation
sample patients was not a study design element. The
distribution of socioeconomic status in the model
sample differed from that in the validation sample;
however, no formal statistical comparisons were
performed.
Table 1 Baseline demographics




study (n = 145)
Validation data set P-value
Continuous variables Mean (SD) Mean (SD)
Age (years) 63.1 (9.98) 46.9 (6.47) <0.001
Weight (kg) 86.6 (19.32) 81.7 (22.34)* 0.011
Years since onset of ostheoarthristis (years) 9.5 (9.59) 9.3 (8.15) 0.416
SF-36 Physical Component scale 28.3 (7.25)† 29.1 (7.87)‡ 0.858
SF-36 Mental component scale 50.8 (11.84)† 48.8 (15.02)‡ 0.077
BMI 32.5 (7.63) 26.7 (5.05)§ <0.001
Discrete variables % %
Gender
Female 70.4 32.4 <0.001
X-ray grade¶
Grade 0 3 NA NA
Grade I 11 NA
Grade II 26 NA
Grade III 34 NA
Grade IV 26 NA
Race











Other knee affected by osteoarthritis 84.7 NA NA
Other knee requires treatment 54.1 NA NA
Joints affected by osteoarthritis (right or left hip,
or spine, or interphalangeal joints (hand),
or thumb carpal meta-carpal joint, or ﬁrst (MTP)
99.6 NA NA
Prior surgery of the study knee (years) 30.59 NA NA
Total number of “now” conditions** NA
1–2 current health problems 14.62 NA
3+ current health problems 1.58 NA
Overall health in the past 4 weeks




Very poor 1.19 NA
Please note that the sample size was n = 255 for the hylan G-F 20 study and n = 145 for the HIP study with the exception of: *n = 141, †n = 253, ‡n = 128, §n = 138.
¶For the validation component using the Alberta HIP Study patients, x-ray grading was not assessed at baseline.
**The total number of medical problems reported from the Clinical Health Assessment Questionnaire A, responses include: high blood pressure, heart attack, other heart
condition, stroke,mental illness, depression, diabetes, cancer, alcohol or drug problem,kidney problem, lung problem, cataract, asthma, severe allergies, liver or gall bladder problem,
ulcers or stomach problem, neurological problem, fracture of spine, thyroid or endocrine disorder, problems with prostate (men) or uterus/ovaries (women).
BMI, body-mass index = weight in kg/(height in m2); MTP, metatarsophalangeal; NA, not available.
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The WOMAC total score (Table 2) differed signiﬁ-
cantly between the model and the validation sample
groups (P = 0.002). The validation sample had con-
sistently lower scores in all three subscales of the
WOMAC (pain, stiffness, and function; P = 0.007,
P = 0.019, and P = 0.001, respectively), indicating that
the validation sample subjects had less morbidity than
the subjects in the model sample.
The mean overall HUI3 utility score at baseline was
0.52 in the validation sample and 0.48 in the model
sample (Table 3, P = 0.957). Although this difference
is not statistically signiﬁcant, it is consistent with the
overall impression from the data that the model
sample patients were less healthy, probably because of
their more advanced age and comorbidities. For
example, the model sample patients had worse vision,
hearing, speech, dexterity, emotion, and cognition.
Interestingly, the only statistically signiﬁcant differ-
ences between the two groups were in the single-
attribute HUI3 utility scores for ambulation and pain,
where the validation sample patients were signiﬁcantly
worse in both. This ﬁnding is consistent with the fact
that these patients were on a waiting list to receive hip
replacement.
Model Performance and Prediction
Table 4 reports the ME, MAE, RMSE, and ICC pre-
diction performance of each of the prediction models 1
to 3 in both the model (hylan G-F 20) and validation
(Alberta HIP) samples (model 4 results are not
reported because information on x-ray grade was
unavailable in the validation sample). Somewhat
surprisingly, the validation sample outperformed the
model sample in three of the four prediction perfor-
mance measures (MAE, RMSE and ICC). The model
sample had a lower ME score than did the validation
sample.
Models that included the WOMAC subscale
scores and their pairwise interaction terms, as well as
demographics (age, age squared, gender), and the
years of OA in the study knee (years of OA, years of
OA squared), that is, model 3 (primary model) and
model 4, performed marginally better as they were
better able to account for the variability in the
response than model 1, which excluded these covari-
ates. The results from the validation sample support
the conclusions from the original study in that the
primary model identiﬁed during development (model
3) consistently performed better on the MAE, RMSE,
ICC, and ME criteria than the secondary models
(models 1 and 2).
Figure 1 illustrates the relationship between the
actual and predicted HUI3 scores for both the model
and the validation samples. A unit change on the hori-
zontal axis is equivalent to a unit change along the
vertical axis; consequently a slope of 1 would be
Table 2 Baseline WOMAC scores
WOMAC scores*
Hylan G-F 20 study
(n = 255)
Model development





WOMAC total score 18.0 (3.95) 16.8 (4.44) 0.002
WOMAC subscale scores
Pain (0–20) 11.6 (2.81) 10.9 (3.34) 0.007
Stiffness (0–8) 5.1 (1.46) 4.8 (1.38) 0.019
Function (0–68) 39.9 (9.25) 36.6 (11.24) 0.001
*The higher the score, the worse the health state.
WOMAC,Western Ontario and McMaster Osteoarthritis Index.
Table 3 Baseline HUI3 utility scores
HUI3 utility scores*
Hylan G-F 20 study
(n = 255)
Model development





Overall 0.48 (0.23) 0.52 (0.21) 0.957
Single attribute utility scores
Vision 0.93 (0.88) 0.96 (0.07) 0.639
Hearing 0.93 (0.19) 0.99 (0.05) 0.999
Speech 0.98 (0.08) 1.00 (0.03) 0.998
Ambulation 0.92 (0.14) 0.82 (0.14) <0.001
Dexterity 0.95 (0.13) 1.00 (0.02) 0.999
Emotion 0.92 (0.16) 0.94 (0.11) 0.909
Cognition 0.92 (0.16) 0.98 (0.06) 0.999
Pain 0.53 (0.25) 0.43 (0.26) <0.001
*The higher the score, the better the overall health utility.
HUI3, Health Utility Index Mark 3.
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indicative of the perfect agreement between the two
measures (i.e., the 45-degree line from the origin to 1;
unity slope).
The slope of the graph of actual versus predicted
HUI3 scores for the model sample (Fig. 1a) does not
equal 1, and more observations fall above the line. The
data points were not uniformly distributed about the
45-degree line as the prediction model both over pre-
dicted HUI3 scores for those with low HUI3 scores
and under predicted HUI scores for those with higher
HUI3 scores. A test of the hypothesis that the inter-
cept = 0 and slope = 1 could not be rejected.
This ﬁnding is conﬁrmed by the ME estimate for the
primary and secondary models (Table 4), which,
although negative, is very close to zero. When regress-
ing the observed HUI3 scores on the predicted HUI3
scores in the validation sample, the equation of the
line was found to be y = 0.059 + 0.906 ¥ (Predicted
HUI3 from Model 3). At the 5% level of signiﬁcance,
there was no evidence that the intercept differs from
zero (P = 0.240) or that the slope differs from one
(P = 0.329). Because the slope is less than one, a greater
proportion of the data points falling (above, if we
reverse the axis, see Fig. 1b) below the theoretical
45-degree slope. This is consistent with the ME esti-
mates for the primary and secondarymodels of Table 4,
which, although close to zero, are larger and more
positive than those from the model sample. In Figure 1,
there is a compression of predicted HUI3 scores
between 0.2 and 0.8, while the actual HUI3 scores for
the samples are more spread out. These data suggest
that the actual HUI “extreme” scores are being under-
estimated in this population. This compression of pre-
dicted scores could be attributed to the differences in the
two instruments, with the WOMAC not being able to
predict the eight attributes of the HUI3 from the two
attributes (ambulation and pain) that it covers.
Discussion
Grootendorst et al. [5] developed models to predict
HUI3 HRQL scores using the WOMAC scores of a
group of individuals with OA of the knee. These
models were used to predict HRQL of a group of
individuals with OA of the hip and thereby validate the
models. These “validation” subjects were drawn from
different geographic locations, had different clinical
presentations, and experienced substantially lower
levels of morbidity than did the subjects used to esti-
mate the models. Despite these differences, the ability
of the models to predict HRQL scores of the validation
subjects actually exceeded the models’ predictive per-
formance in the original model subjects.
There are several limitations to the present analy-
sis. First, in the validation data set, x-ray grade was
not measured alongside other clinical demographics.
As such, the model prediction estimates could not be
examined without making assumptions about base-
line x-ray grade. Second, the sample size in the vali-
dation sample was driven by the nature of the
intervention and thus data post baseline were not
utilized as the intervention essentially altered the
Table 4 Comparison of model performance criteria
Performance criterion
Hylan G-F 20 study









Lower Upper Lower Upper
MAE Model 1 0.1645 0.1486 0.1798 0.1382 0.1221 0.1548
Model 2 0.1652 0.1488 0.1813 0.1375 0.1214 0.1544
Model 3 0.1629 0.1457 0.1779 0.1360 0.1195 0.1524
RMSE Model 1 0.2083 0.1872 0.2290 0.1698 0.1496 0.1898
Model 2 0.2096 0.1868 0.2310 0.1713 0.1526 0.1905
Model 3 0.2066 0.1846 0.2273 0.1684 0.1480 0.1885
ICC Model 1 0.5360 0.4513 0.6109 0.5676 0.4725 0.6539
Model 2 0.5379 0.4536 0.6134 0.5642 0.4683 0.6456
Model 3 0.5557 0.4696 0.6293 0.5745 0.4805 0.6593
ME Model 1 -0.0007 -0.0442 0.0412 0.0179 -0.0126 0.0434
Model 2 -0.0005 -0.0431 0.0427 0.0175 -0.0129 0.0440
Model 3 -0.0006 -0.0422 0.0397 0.0120 -0.0183 0.0376
*Percentile 95% conﬁdence intervals obtained from the distribution (of MAE, RMSE, ICC or ME).
RMSE, Root mean square error; MAE, Mean square error; ME, mean error; ICC, Intra-class correlation coefﬁcient.
Model 1 =WOMAC.
Model 2 =WOMAC +DEMOG.
Model 3 [Primary Model] =WOMAC +DEMOG + YRSOA.
WOMAC = f {Pain, Stiffness, Function (Pain ¥ Stiffness) (Pain ¥ Function) (Stiffness ¥ Function), Pain2, Stiffness2, Function2].
DEMOG = f {Age,Age2, Gender}.
YRSOA = f {Years since onset of OA,Years since onset of OA2].
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patient’s fundamental OA status. Had the interven-
tion been different, perhaps data post baseline could
have been utilized, resulting in a larger sample size
and more robust validation estimates. Third, the fact
that validation sample subjects had lower WOMAC
scores (i.e., less morbidity from OA) than model
sample subjects was not anticipated. A priori, we
expected greater morbidity in the validation study
group as these subjects underwent “hip replacement”
as opposed to model study subjects, who received
intra-articular injections to reduce pain in the hip/
knee. One reason for this is that validation subjects
were younger and had less comorbidity than the
average hip replacement patient. The mean age for
total hip arthroplasty in the general population has
been reported as 62 years [12], compared with
47 years in the validation sample. It seems likely
that validation subjects had worn out hips because
of more intense physical activity and might not
necessarily be representative of patients with hip
replacements.
Finally, although the prediction models are able
reliably to predict group average utility scores, they
cannot accurately predict patient level utility scores, as
utility scores vary because of dysfunction in health
domains not captured in the WOMAC. For patient-
level analyses, we recommend that utility scores be
measured directly.
Conclusions
The prediction models developed by Grootendorst
et al. [5] were validated by Alberta HIP study data.
These models provide researchers with a tool that can
reliably allow mapping of disease-speciﬁc HRQL
scores measured with WOMAC into utility scores for
use in situations where directly measured preference-
based HRQL data are unavailable. The predicted
utility scores can be used to calculate QALYs for cost-
effectiveness analysis in clinical and economic apprais-
als of interventions that target chronic diseases, such as
OA, which affect primarily functional capacity, not
longevity. One must, however, use caution using this
tool, as it was developed to function on a group level
and should not be applied to predict patient-level
utility.
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Figure 1 (a) Predicted versus actual HUI3 score—Hylan G-F 20 Study.
(b) Predicted versus actual HUI3 score—Alberta HIP Study. HUI3, Health
Utilities Index Mark 3.
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